Abstract Heparin and low-molecular weight heparin (LMWH) are complex, heterogeneous polysaccharides used in the treatment of arterial and venous thrombosis. M118 is a novel LMWH with low polydispersity and pronounced anti-Xa and anti-thrombin (IIa) activity as compared to current LMWHs. To determine if M118 is effective in preventing thrombosis in the setting of a vascular plaque, apolipoprotein E knockout mice fed a high fat diet were injected with M118, enoxaparin, unfractionated heparin, or saline control and examined for arterial thrombosis using a rose bengal laser induced carotid artery injury model. M118 significantly increased the time to occlusion as compared to control and unfractionated heparin but not compared to enoxaparin although fewer M118 treated animals had any vascular occlusion present at the time of protocol completion. Platelet-neutrophil aggregates were studied by flow cytometry and were found to be decreased with M118 as compared to enoxaparin. This is the first published report examining M118, a novel LMWH designed to have low polydispersity and enhanced anticoagulant activity. In an animal model of vascular plaque,
Introduction
Arterial and venous thromboses are major causes of cardiovascular morbidity and mortality and arterial thrombosis is the most common cause of myocardial infarction and stroke [1] . In the acute treatment of arterial thrombi, strategies that target both platelet activation and the generation of fibrin have led to the greatest clinical success [2, 3] . New anticoagulant drugs for the prevention and treatment of vascular thrombosis have focused on improved efficacy, predictable dosing in a wide range of patients, and, importantly, acceptable bleeding risk [2] .
Heparin has played a central role in the treatment of arterial and venous thrombosis [4] . Unfractionated heparin's primary mechanism is to accelerate antithrombin's (ATIII) inhibition of thrombin (IIa), factor Xa, and factor IXa [5] . Binding of ATIII to a specific heparin pentasaccharide sequence causes protein conformational change that regulates ATIII [6, 7] . The formation of a ternary complex between ATIII, thrombin, and heparin leads to the inactivation of thrombin [8] . Heparin's anti-Xa activity requires the ATIII pentasaccharide-binding site but its antiIIa activity requires at least 18 saccharide units for the formation of a complete complex [8] .
Heparin is limited by its chemical heterogeneity and polydispersity, which cause nonspecific protein binding and variable pharmacokinetics. Low-molecular weight heparins (LMWHs) have both less polydispersity and reduced chain length as compared to heparin. They also have reduced anticoagulant activity and are unable to be neutralized by protamine. To circumvent these limitations, a novel LMWH was designed with low polydipersity and enhanced anti-Xa and anti-IIa activity. M118 is a rationally engineered LMWH designed specifically to embody the physicochemical and biological properties of an ideal heparin, i.e., decreased polydispersity; pronounced antiFactor Xa and anti-Factor IIa activity; ability to stimulate tissue factor pathway inhibitor release from the endothelium; favorable pharmacokinetics with high subcutaneous bioavailability; and reversibility with protamine sulfate. The concept behind the potential creation of a rationally designed LMWH was first described by Sundaram et al. [9] and later modified to achieve the compound M118 (Fig. 1) . To determine its efficacy in the setting of vascular plaque disruption, M118 was studied in apolipoprotein E knockout mice (ApoE -/-) and compared to enoxaparin and UFH (unfractionated heparin).
Materials and methods

Chemical and reagents
M118, enoxaparin and UFH were supplied by Momenta Pharmaceuticals, Inc (Cambridge, MA). M118 has a structural formula of C 12m H 14m?1 O 10m N m Na m R 3m-1 R1 m , C 12m H 14m?2 O 10m?1 N m Na m R 3m R1 m , where n = number of disaccharide repeats, m = 1 ? n, R is H or SO 3 Na, and R1 is SO 3 Na or COCH 3 (Fig. 1) . The stereo centers present in M118 were derived from unfractionated heparin starting material, which in turn were established during the biosynthesis of heparin. Heparin building blocks containing chiral centers include D-glucosamine, D-glucuronic acid and L-iduronic acid.
Rose Bengal was procured from Chemsavers, Inc (Powhatan, VA). Anti-integrin aIIb antibody (clone H-160) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Biotinylated anti-rabbit IgG and Vectastain Elite ABC kit were obtained from Vector Laboratories (Burlingame, CA). Western diets were purchased from Research Diets (New Brunswick, NJ). All other standard chemicals, unless specified, were obtained from Sigma (St Louis, MO).
Drug preparations
Drug solutions were freshly prepared aseptically with saline just prior to infusion into the mice. UFH and M118 were used at a dose of 1 mg/kg mouse body weight. Enoxaparin was given at 2 mg/kg body weight in order to match M118 for the level of anti-Factor Xa activity. Equal volumes of sterile saline solution were given as control.
Plasma anti-coagulant activity
Female ApoE( -/-) mice were injected with saline control, M118 (1 mg/kg) or Heparin (1 mg/kg); enoxaparin (2 mg/kg) before 20 min exposure of laser based arterial injury. Citrated plasma samples were measured for Anti-Xa or Anti-IIa activity. Blood plasma anti-factor Xa and anti-IIa activities were evaluated using a modified amidolytic method run on an automated Diagnostica Stago STA-R analyzer, where CBS 31.39 and S-2238 were used as the chromogenic substrate.
ApoE
-/-mice and western diet
The use of ApoE -/-mice in a model of photochemical laser injury was approved by IACUC of the Boston University Medical School. Male and female mice were used in the study. The ApoE -/-mice, 4-6 weeks old (Jackson Laboratories, Bar Harbor, ME) were maintained on a western chow diet for 12 weeks to generate vascular plaques [10, 11] . Mice were routinely monitored for weight change twice per week in the beginning and subsequently their weights were monitored at least once a week for the remainder of the study. Mice were also checked for signs of lethargy, immobility, weight loss, and labored breathing during the entire study. Any animal that lost more than 20% of its body weight was euthanized.
Photochemical carotid artery injury model After 12 weeks of a western diet, mice were anesthetized with isofluorane in a chamber and were initially maintained with continuous isoflurane inhalation through a nose cone. The mice were placed on a heating pad to prevent hypothermia during the surgery. The left femoral vein was isolated and cannulated with silastic tubing (PE10, 0.61 mm O.D.), which was later used to administer the study drug. A midline cervical incision was made to expose Fig. 1 The structure of M118 M118, a novel low-molecular weight heparin 395 the trachea and isolate the right common carotid artery. A lateral incision was made in the trachea; endotracheal intubation was then accomplished with an 18G blunt needle. A rodent respirator was used to ventilate the mice mechanically with 21% oxygen, and 2% isoflurane, at a rate of 80 breaths per minute and a stroke volume of 0.3 ml. The carotid artery was encircled with a doppler flow probe and monitored with a flow meter (Transonic Systems, T206). The area around the carotid artery was filled with normal saline at 37°C. The animals were then given UFH, M118, enoxaparin, or saline control through the left cannulated femoral vein. After administration of the drug, a chemical photosensitizer, Rose Bengal (50 mg/kg in PBS) was infused through the same femoral cannula. After administration of both agents, the Rose Bengal was activated by focusing a 1.5 mW green laser light (540 nm) on the common carotid artery. The laser source was positioned 5 cm from the artery [12] . Arterial thrombus formation by Rose Bengal is accompanied by singlet oxygen generated by the laser excited photosensitizer to molecular oxygen. Blood flow in the vessel was monitored from the time of laser activation to stable vessel occlusion (blood flow of 0 ml/min for 3-5 min) or until 60 min had elapsed. Images of the laser/Rose Bengal generated arterial thrombus were captured by a digital camera. Blood samples (in 10% sodium citrate) were collected by terminal cardiac puncture after the established endpoint. The arterial segment of the laser-exposed region was excised and stored in 2% formaldehyde/PBS for subsequent immunohistochemical analyses. A fraction of the blood sample was used for flow cytometric determination of platelet-neutrophil conjugate formation. The residual blood samples were used for plasma isolation. The supernatant plasma was immediately stored at -70°C for further analysis.
Bleeding time determination
Bleeding times were determined by a tail vein method. Female ApoE -/-mice were anaesthetized using isoflurane. Mice were infused with the drugs as described above. Bleeding times were measured after 5 min of drug infusion. Briefly, bleeding time was measured after severing a 3-mm segment of the mouse tail. The amputated tail was examined for cessation of bleeding using a blotting paper. The time required for the stream of blood to stop was defined as the bleeding time.
Flow cytometry
Blood samples were stained for neutrophils (Phycoerythrin-Cy7 anti-mouse CD14) and platelets (Fluorescein isothiocyanate anti-mouse CD41) for the analysis of the extent of platelet-neutrophil conjugation (platelet positive neutrophils) as described earlier [13, 14] . Briefly, blood samples were mixed with PE-Cy7-CD14 and CD41-FITC or corresponding isotype control antibody. Red blood cells were then lysed. Samples were analyzed by flow cytometry (FACScan using BD Cellquest Pro v5.2 software), using corresponding isotype controls to set up the parameters. 1500-2500 total neutrophils were counted per sample.
Immunohistological analysis
Immunohistochemical staining of the arterial thrombi formed following laser photochemical injury was carried out using a platelet integrin aIIb specific antibody, in a similar manner as described earlier [15, 16] . Briefly, tissue sections were deparaffinized in xylene for 5 min and rehydrated in decreasing concentrations of ethanol. The sections were boiled in antigen unmasking solution (pH 6.0) for 20 min and cooled to room temperature. The sections were quenched in 0.3% H 2 O 2 -methanol for 30 min, followed by blocking with 10% normal goat serum for 30 min. The sections were treated with rabbit antimouse integrin aIIb polyclonal antibody (1:50 in blocking buffer) overnight at 4°C. Sections were washed and then incubated with a biotinylated anti-rabbit IgG at 1:100 dilutions. Sections were then treated with avidin-biotin complex followed by incubation with substrate, 3,3'-diaminobenzidine according to the manufacturer's instruction (Vectastain Elite ABC kit, Vector Laboratories). Sections were counterstained with hematoxylin and then mounted with a coverslip. Corresponding tissue sections without primary antibody served as a negative control. Tissue section images were captured in a Zeiss Axio2 microscope using the SPOT software. Quantitation of DAB stained areas were carried out as described by Brey et al. [17] . Briefly, positively stained areas in DAB stained tissues were manually selected using the ''paint brush'' and ''region of interest'' tools in Photoshop. Selected areas were quantitated using Image J software. At least three independent samples were quantitated in unbiased manner.
Statistical analysis
Anti-Xa and anti-IIa activity were analyzed by one-way ANOVA. Bleeding time data were also analyzed by oneway ANOVA, followed by a Bonferroni's Multiple Comparison Post-Test. Thrombus formation time was analyzed by a non-parametric Kruskal-Wallis test, followed by the Dunn's Multiple Comparison Post-Test. Statistical analysis of the immunohistochemical samples were carried out by one-way ANOVA.
Results
Drug induced enhancement of anticoagulant activity
We determined the effectiveness of M118 (structure shown in Fig. 1 ) and compared it to the established anticoagulants, enoxaparin, and heparin in ApoE -/-mice that had received laser induced clot formation in the carotid artery. Plasma from control ApoE -/-mice treated with saline and subsequent vascular injury had little to no anti-Xa or antiIIa activity (Table 1) . However, treatment of ApoE -/-mice with study drugs led to considerable induction of both anti-Xa and anti-IIa activities. In order to conduct direct comparisons between the activities of the different treatment groups, all three study drugs (M118, UFH, and enoxaparin) were measured against the 2nd International LMWH standard. Notably, UFH led to the highest anti-Xa and -IIa activity (Table 1) when run against the 2nd International LMWH standard. M118 and enoxparin have similar anti-Xa activities at the doses utilized, but M118 had significantly higher anti-IIa activity. Consistent with known properties, both M118 and heparin led to greater enhancement of anti-IIa activity than did enoxaparin (P \ 0.05) by either means of measurement. Overall, these results indicate that heparin is an effective inhibitor of IIa and Xa and, as expected, enoxaparin is an effective inhibitor against Xa. M118 demonstrates inhibition of activity against Xa and IIa but less so than UFH.
Effect of M118 on bleeding time in ApoE
-/-mice Next, we determined whether these changes seen with the anticoagulant compounds were associated with bleeding time alteration in ApoE -/-mice. Mice were infused with the drugs as described and tail vein bleeding times were measured after 5 min of drug infusion. M118 and enoxaparin significantly increased the bleeding time in ApoE -/-mice as compared to saline infusion (Fig. 2) .
Effect of M118, heparin, and enoxaparin on arterial thrombosis
To determine whether M118 has anti-thrombotic properties in the setting of vascular plaque, the carotid artery of ApoE -/-mice was subjected to photochemical injury. Parallel studies were also conducted with heparin, enoxaparin, and a saline control. Thrombus formation was continuously monitored by recording blood flow using a Doppler placed around the carotid artery (Fig. 3a) . Clot accumulation was monitored in parallel using a dissecting microscope. The comparative ability of M118 to prevent photochemical induced thrombus generation is shown in Fig. 3a . As shown in this figure, heparin does not effectively prevent thrombus formation in a photochemical arterial injury model. The effect of these study drugs in preventing the formation of arterial thrombus is summarized in Fig. 3b (a representative plot of blood flow versus Rose Bengal/laser exposure time for M118 versus control is shown in Fig. 3c ). The time to occlusion was significantly longer in mice treated with M118 (58.8 ± 3.5 min) than in control and UFH (24.4 ± 7.4; 39.9 ± 8.6 min, P \ 0.05) but not statistically significantly different as compared to enoxaparin (54.9 ± 10.2 min) treated animals (Fig. 3b) . Only one out of eight mice treated with M118 had any vascular occlusion at the time of protocol completion (60 min). This is as compared to 7/8 UFH treated animals and 3/8 enoxaparin treated animals demonstrating evidence of vascular occlusion. These results show that M118 is a potent inhibitor of arterial thrombosis in the setting of vascular plaque formation. Despite lower in vivo anti-Xa and anti-IIa activity levels, M118 was superior to UFH in the prevention of Rose Bengal induced arterial thrombosis in ApoE -/-mice. M118 was also better than enoxaparin at preventing thrombosis when the study drugs provided approximately the same degree of anti-Xa inhibition. Female ApoE -/-mice were injected with saline control, 1 mg/kg M118, 1 mg/kg Heparin; 2.0 mg/kg enoxaparin before 20 min exposure of laser based arterial injury. Citrated plasma samples were measured for Anti-Xa or Anti-IIa activity using the 2nd International LMWH standard * P = 0.4 vs. UFH; # P = 0.02 vs. enoxaparin; ** P = 0.03 vs. UFH Fig. 2 M118 increases the bleeding time in ApoE -/-mice. Female ApoE -/-mice, placed on a high fat diet were treated with heparin, M118, enoxaparin, or saline control before bleeding times were determined by the tail vein method. The graph represents the average bleeding time for each group; n = 3 for heparin and enoxaparin treatments, and n = 4 for M118 and control (** P \ 0.01, *** P \ 0.001) M118, a novel low-molecular weight heparin 397
Effects of anticoagulants on the inflammatory response following arterial injury
The interaction between circulating white cells and platelets was shown to increase in patients with unstable coronary syndromes in the setting of coronary cathertization [18] [19] [20] [21] . To determine whether arterial injury could elicit a similar inflammatory response in this pre-clinical model, we analyzed platelet-neutrophil conjugates after pretreating with the study drugs. Female ApoE -/-mice were treated with UFH, M118, enoxaparin, or saline control and were subjected to the photochemical arterial injury procedure for 20 min. Pretreatment with M118 or UFH produced considerably fewer platelet-neutrophil conjugates (Fig. 4) .
Immunohistochemical study of arterial sections and the effect of M118, heparin, and enoxaparin on thrombus development Prevention of arterial thrombus by M118 following photochemical induced thrombosis was verified by immunohistochemical staining. Laser exposed arterial sections were subjected to immunohistochemical staining after incubating with a platelet specific antibody, intergrin aIIb.
The integrin aIIb was observed in control, heparin, and enoxaparin treated samples as indicated by the strong brown staining, but not significantly in M118 treated specimens (Fig. 5a, b) . This staining pattern is consistent Fig. 3 M118 prevents thrombotic occlusion in a rose bengal laser induced thrombotic model in western diet fed ApoE( -/-) mice. a M118, but not heparin, prevents thrombus formation in ApoE -/-mice with vascular plaque. Western diet fed male ApoE -/-mice were subjected to an arterial injury procedure after infusion of corresponding drugs as described in the methods section. Images of thrombus was captured by a digital camera after the green laser light was switched off (Representative images for heparin, M118, and control treated samples are shown). b M118 prevents thrombotic occlusion following photochemical injury in western diet fed ApoE -/-mice. Western diet fed male ApoE -/-mice were subjected to photochemical injury after infusion of heparin, M118, enoxaparin, or saline control as described in the methods section. Stable thrombus formation was characterized by the lack of blood flow through the artery for 3-5 min and verified by direct monitoring of stable thrombus through the dissecting scope. The experiment was terminated at 60 min if no thrombus formation was observed (dotted line on the graph). The plot represents the average time for each group for a stable thrombus formation (n = 8 for all groups; * P \ 0.05 vs. control and heparin). mice on a high fat diet were treated with heparin, M118, enoxaparin, or saline and subjected to the photochemical arterial injury procedure for 20 min. Blood samples were drawn by a terminal cardiac puncture in 10% sodium citrate solution. Blood samples were stained for neutrophils (phycoerythrin-Cy7 anti-mouse CD14) and platelets (fluorescein isothiocyanate anti-mouse CD41). Samples were analyzed by flow cytometry following lysis of red blood cells. Respective isotype control antibody-treated blood was used for parameter setup. Average values for the duplicate sample sets were used for the plot with the ability of M118 to attenuate platelet accumulation in ApoE -/-mice with vascular plaque (Fig. 3) .
Discussion
Thrombotic complications of vascular disease constitute the leading cause of morbidity and mortality in much of the developed world. However, current drug therapies available to treat the thrombotic component of arterial and venous vascular complications remain limited [22] . Limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs to prevent and treat both venous and arterial thromboembolism [23] . Arterial thrombi typically consist of platelet aggregates held together by small amounts of fibrin. Strategies to inhibit arterial thrombogenesis are primarily focused on drugs that block platelet function.
However, these strategies usually include anticoagulants that prevent fibrin deposition, which is ideal for unstable coronary syndromes. Anticoagulant strategies to inhibit thrombosis have focused on blocking initiation of coagulation, preventing propagation of IIa, or inhibiting its activity. Additionally, the inability of heparin to inactivate fibrin-bound IIa allows enhanced thrombus growth suggesting that other means of inhibition might be beneficial [23] . Current evidence suggests that high doses of heparin should be avoided after an acute ischemic stroke, as the results of recent large trials suggest any potential treatment benefit in preventing deep vein thrombosis (DVT) is cancelled by the increased intracranial bleeding risk caused from the underlying disease [24] .
To achieve the anticoagulant benefits of both heparin and LMWH, a novel LMWH (M118) was designed with low polydipersity and enhanced anti-Xa and anti-IIa activity. In the current study, we examined the effectiveness of M118 in preventing thrombosis in the setting of vascular plaque. By using a photochemical carotid artery injury model in ApoE -/-mice, we are able to show the ability of M118 to prevent arterial thrombosis in diseased arteries. Our study also shows that M118 can effectively attenuate the formation of platelet-leukocyte conjugates. Since circulating monocyte-platelet aggregates are a sensitive early marker of in vivo platelet activation and acute myocardial infarction [19, 25] , attenuation of platelet-neutrophil aggregates by M118 is consistent with its anti-thrombotic and possible antiinflammatory characteristics. Platelet-neutrophil conjugate formation was effectively attenuated by UFH and M118, but not by enoxaparin. The reason for these differences cannot be inferred from the current data.
In the present study, a single dose of M118 was selected because the purposes of the study were to match products/ doses based on anti-Xa and anti-IIa activity. It is worth mentioning that Cmax (peak level) of M118 is achieved following intravenous bolus at zero time point (T0) and the levels fall off thereafter (Personal Communication, Momenta Pharmaceuticals). Additionally, in the present study, the blood was collected for coagulation parameters following 20 min of drug administration. As there is a limited blood volume that can be collected, it was only possible to collect a single time point and the bleed was terminal. Although this study does not provide the direct data, it is likely that at 20 min the results would be similar as all three tested compounds have comparable pharmacokinetics following intravenous injections (Personal Communication, Momenta Pharmaceuticals). Interestingly, at relative time points following injury, there was still a difference in rates of thrombotic occlusion despite differences in the plasma concentration of the products based upon anti-Xa and anti-IIa activity. 5 Immunohistochemical staining demonstrates that M118 but not heparin or enoxaparin prevents arterial injury mediated thrombus formation in ApoE -/-mice. a Laser/photochemical injured arterial sections from western diet fed male ApoE -/-mice were subjected to platelet thrombus specific integrin aIIb staining by immunohistochemical procedure as described in the methods section. Presence of platelet specific integrin aIIb (brown staining) is evident in representative images from saline, heparin, and enoxaparin treated samples but not in M118 treated specimens. b Quantification of DAB (brown) stain in a as described in the Methods section (* P \ 0.004, ** P \ 0.01; n = 3)
Overall, this study shows that M118 is an effective antithrombotic and anticoagulant compound in this model, which can efficiently prevent arterial thrombosis induced by laser photochemical injury. While these studies suggest efficacy in the setting of unstable coronary syndromes and vascular plaque disruption, future clinical studies will determine the ability of M118, relative to existing therapies, to prevent vascular occlusion with tolerable bleeding risk.
